Subtype
Neuroendocrine Carcinoma
CI-CAN-00001275NECExplore in graph →
514 active trials12 approved drugs28 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001275NECExplore in graph →
Clinical trials
1,533 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (213)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05546268 | Study of Oral MRT-2359 in Selected Cancer Patients | active not recruiting | Phase 1 / Phase 2 | 174 | Monte Rosa Therapeutics, IncINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04471727 | A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) | active not recruiting | Phase 1 / Phase 2 | 232 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Feb 24, 2026 |
| clinicaltrials |
| NCT07030257 | Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Tasca TherapeuticsINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07413042 | A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment | recruiting | Phase 1 | 24 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07414927 | A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy | not yet recruiting | Phase 1 / Phase 2 | 48 | Shanghai Best-Link Bioscience, LLCINDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03830918 | Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy | active not recruiting | Phase 1 / Phase 2 | 59 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07107490 | A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER | recruiting | Phase 1 | 122 | Chugai PharmaceuticalINDUSTRY | 3 | Feb 6, 2026 | clinicaltrials |
| NCT06939036 | Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )(SANTANA-225) | terminated | Phase 1 / Phase 2 | 2 | Ariceum Therapeutics GmbHINDUSTRY | 2 | Feb 5, 2026 | clinicaltrials |
| NCT04640480 | Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors | completed | Phase 1 | 21 | SN BioScienceINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT03467360 | Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma(ICAR) | recruiting | Phase 1 | 27 | Centre Antoine LacassagneOTHER | 2 | Jan 20, 2026 | clinicaltrials |
| NCT03575793 | A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 39 | Salma SabbourOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | terminated | Phase 1 / Phase 2 | 73 | Ocellaris Pharma, Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05490472 | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Jan 9, 2026 | clinicaltrials |
| NCT03899792 | A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors(LIBRETTO-121) | active not recruiting | Phase 1 / Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 11 | Jan 6, 2026 | clinicaltrials |
| NCT05978284 | Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma | recruiting | Phase 1 / Phase 2 | 54 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07038096 | ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma | recruiting | Phase 1 / Phase 2 | 350 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT03556228 | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | recruiting | Phase 1 / Phase 2 | 242 | VM Oncology, LLCINDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT05120271 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors(DUET-1) | active not recruiting | Phase 1 / Phase 2 | 7 | Sotio Biotech Inc.INDUSTRY | 2 | Dec 5, 2025 | clinicaltrials |
| NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 350 | GV20 TherapeuticsINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07252661 | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 40 | AccSalus Biosciences, Inc.INDUSTRY | 0 | Nov 28, 2025 | clinicaltrials |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 31 | TransgeneINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT03319940 | Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) | active not recruiting | Phase 1 | 269 | AmgenINDUSTRY | 13 | Nov 19, 2025 | clinicaltrials |
| NCT06283719 | Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 265 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03582475 | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | active not recruiting | Phase 1 | 15 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT06062745 | Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT | recruiting | Phase 1 | 30 | Brigham and Women's HospitalOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT05244239 | Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer | recruiting | Phase 1 | 22 | Emory UniversityOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT03901573 | High-Risk Skin Cancers With Atezolizumab Plus NT-I7 | terminated | Phase 1 / Phase 2 | 31 | NeoImmuneTechINDUSTRY | 1 | Oct 22, 2025 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT03392064 | A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC | suspended | Phase 1 | 6 | AmgenINDUSTRY | 1 | Oct 15, 2025 | clinicaltrials |
| NCT06940440 | IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) | recruiting | Phase 1 | 9 | TuHURA Biosciences, Inc.INDUSTRY | 1 | Oct 15, 2025 | clinicaltrials |
| NCT05329623 | A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants. | completed | Phase 1 | 33 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 10, 2025 | clinicaltrials |
| NCT04631029 | Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread | completed | Phase 1 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07206563 | Penfluridol for Relapsed/Refractory Small Cell Cancers | not yet recruiting | Phase 1 / Phase 2 | 33 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT04885998 | AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) | completed | Phase 1 | 23 | AmgenINDUSTRY | 6 | Sep 29, 2025 | clinicaltrials |
| NCT02514447 | Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy | completed | Phase 1 / Phase 2 | 123 | G1 Therapeutics, Inc.INDUSTRY | 8 | Sep 25, 2025 | clinicaltrials |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 23 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06805825 | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | recruiting | Phase 1 | 67 | Novelty Nobility, Inc.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06505824 | A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT03647163 | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 33 | Vyriad, Inc.INDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT01737502 | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 29 | Mayo ClinicOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06016270 | A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 10 | STCube, Inc.INDUSTRY | 2 | Sep 5, 2025 | clinicaltrials |
| NCT07141771 | An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing | not yet recruiting | Phase 1 / Phase 2 | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT03708328 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 134 | Hoffmann-La RocheINDUSTRY | 6 | Aug 20, 2025 | clinicaltrials |
| NCT07132957 | A Study of AL8326 in Healthy Subjects | completed | Phase 1 | 6 | Advenchen Laboratories Nanjing Ltd.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT07110363 | A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer | not yet recruiting | Phase 1 | 58 | Biotroy TherapeuticsINDUSTRY | 0 | Aug 7, 2025 | clinicaltrials |
| NCT06592638 | A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer | recruiting | Phase 1 | 30 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | terminated | Phase 1 | 5 | Craig L Slingluff, JrOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | Incyte CorporationINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Mar 3, 2026source: clinicaltrials